Test Bank - Pharmacotherapeutics for Advanced Practice Nurse Prescribers, 6th Edition (Woo, 2024), Chapter 1-57 | All Chapters |complete Guide A+.

,Test Bank Pharmacotherapeutics forAdvanced Practice Nurse
i.l i.l i.l i.l i.l i.l




Prescribers 6e Teri Moser Woo
i.l i.l i.l i.l i.l




Chapter 1. The Role of the Advanced Practice Nurse as Prescriber
i.l i.l i.l i.l i.l i.l i.l i.l i.l i.l




MULTIPLE CHOICE i.l




1. Nurse practitioner prescriptive authority is regulated by:
i.l i.l i.l i.l i.l i.l



A. The National Council of State Boards of Nursing i.l i.l i.l i.l i.l i.l i.l



B. The U.S. Drug Enforcement Administration i.l i.l i.l i.l



C. The State Board of Nursing for each state i.l i.l i.l i.l i.l i.l i.l



D. The State Board of Pharmacy i.l i.l i.l i.l




ANS: i . l C PTS: i . l 1

2. The benefits to the patient of having an advanced practice registered nurse (APRN)
i.l i.l i.l i.l i.l i.l i.l i.l i.l i.l i.l i.l



prescriberinclude:
i.l i.l



A. Nurses know more about pharmacology than other prescribers because they take
i.l i.l i.l i.l i.l i.l i.l i.l i.l i.l



itboth in their basic nursing program and in their APRN program.
i.l i.l i.l i.l i.l i.l i.l i.l i.l i.l i.l i.l



B. Nurses care for the patient from a holistic approach and include the patient
i.l i.l i.l i.l i.l i.l i.l i.l i.l i.l i.l i.l



indecision-making regarding their care.
i.l i.l i.l i.l i.l



C. APRNs are less likely to prescribe narcotics and other controlled substances. i.l i.l i.l i.l i.l i.l i.l i.l i.l i.l



D. APRNs are able to prescribe independently in all states, whereas a i.l i.l i.l i.l i.l i.l i.l i.l i.l i.l



physician’sassistant needs to have a physician supervising their practice.
i.l i.l i.l i.l i.l i.l i.l i.l i.l i.l




ANS: i . l B PTS: i . l 1

3. Clinical judgment in prescribing includes: i.l i.l i.l i.l



A. Factoring in the cost to the patient of the medication prescribed i.l i.l i.l i.l i.l i.l i.l i.l i.l i.l



B. Always prescribing the newest medication available for the disease process i.l i.l i.l i.l i.l i.l i.l i.l i.l



C. Handing out drug samples to poor patients i.l i.l i.l i.l i.l i.l



D. Prescribing all generic medications to cut costs i.l i.l i.l i.l i.l i.l




ANS: i . l A PTS: i . l 1

4. The process for choosing an effective drug for a disorder includes:
i.l i.l i.l i.l i.l i.l i.l i.l i.l i.l



A. Asking the patient what drug they think would work best for them i.l i.l i.l i.l i.l i.l i.l i.l i.l i.l i.l



B. Consulting nationally recognized guidelines for disease management i.l i.l i.l i.l i.l i.l



C. Prescribing medications that are available as samples before writing a prescription i.l i.l i.l i.l i.l i.l i.l i.l i.l i.l



D. Following U.S. Drug Enforcement Administration guidelines for prescribing i.l i.l i.l i.l i.l i.l i.l




ANS: i . l B PTS: i . l 1

5. Nonintentional nonadherence of drug therapy may occur due to: i.l i.l i.l i.l i.l i.l i.l i.l



A. Belief that medication does not work i.l i.l i.l i.l i.l



B. Adverse drug reactions i.l i.l



C. Chronic conditions that require daily therapy i.l i.l i.l i.l i.l



D. Forgetfulness or distraction i.l i.l




ANS: i . l D PTS: i . l 1

, Woo 1
Pharmacotherapeutics for APN Prescribers, 6e i.l i.l i.l i.l Ch02


Chapter 2. Review of Basic Principles of Pharmacology
i.l i.l i.l i.l i.l i.l i.l




MULTIPLE CHOICE i.l




1. A patient’s nutritional intake and laboratory results reflect hypoalbuminemia. This is
i.l i.l i.l i.l i.l i.l i.l i.l i.l i.l



criticalto prescribing because:
i.l i.l i.l i.l



A. Distribution of drugs to target tissue may be affected. i.l i.l i.l i.l i.l i.l i.l i.l



B. The solubility of the drug will not match the site of absorption.
i.l i.l i.l i.l i.l i.l i.l i.l i.l i.l i.l



C. There will be less free drug available to generate an effect. i.l i.l i.l i.l i.l i.l i.l i.l i.l i.l



D. Drugs bound to albumin are readily excreted by the kidneys. i.l i.l i.l i.l i.l i.l i.l i.l i.l




ANS: i . l A PTS: i . l 1

2. Drugs that have a significant first-pass effect:
i.l i.l i.l i.l i.l i.l



A. Must be given by the enteral (oral) route only i.l i.l i.l i.l i.l i.l i.l i.l



B. Bypass the hepatic circulation i.l i.l i.l



C. Are rapidly metabolized by the liver and may have little, if any, desired action
i.l i.l i.l i.l i.l i.l i.l i.l i.l i.l i.l i.l i.l



D. Are converted by the liver to more active and fat-soluble forms
i.l i.l i.l i.l i.l i.l i.l i.l i.l i.l




ANS: i . l C PTS: i . l 1

3. The route of excretion of a volatile drug will likely be the:
i.l i.l i.l i.l i.l i.l i.l i.l i.l i.l i.l



A. Kidneys
B. Lungs
C. Bile and feces i.l i.l



D. Skin
ANS: i . l B PTS: i . l 1

4. A major disadvantage to IV administration is that:
i.l i.l i.l i.l i.l i.l i.l



A. First-pass metabolism is eliminated. i.l i.l i.l



B. Needles and sterility are required. i.l i.l i.l i.l



C. Absorption of the drug cannot be slowed after administration. i.l i.l i.l i.l i.l i.l i.l i.l



D. It is significantly more expensive than other routes.
i.l i.l i.l i.l i.l i.l i.l




ANS: i . l C PTS: i.l i.l i . l 1

5. The nurse practitioner (NP) chooses to give cephalexin every 8 hours based on knowledge
i.l i.l i.l i.l i.l i.l i.l i.l i.l i.l i.l i.l i.l



i.l ofthe drug’s:
i.l i.l



A. Propensity to go to the target receptor i.l i.l i.l i.l i.l i.l



B. Biological half-life i.l



C. Pharmacodynamics
D. Safety and side effects i.l i.l i.l




ANS: i . l B PTS: i . l 1

6. Deferasirox is a chelating agent used to treat iron overload by binding iron to render i.l i.l i.l i.l i.l i.l i.l i.l i.l i.l i.l i.l i.l i.l



i.l itbiologically inactive. This is best characterized as a(n):
i.l i.l i.l i.l i.l i.l i.l i.l

, Woo 2
Pharmacotherapeutics for APN Prescribers, 6e i.l i.l i.l i.l Ch02


A. Nonreceptor mechanism i.l



B. Partial agonist i.l



C. Full agonist i.l



D. Noncompetitive antagonist i.l




ANS: i . l A PTS: i . l 1

7. The point in time on the drug concentration curve that indicates the first sign of a
i.l i.l i.l i.l i.l i.l i.l i.l i.l i.l i.l i.l i.l i.l i.l



therapeuticeffect is the:
i.l i.l i.l i.l



A. Minimum adverse effect level i.l i.l i.l



B. Peak of action i.l i.l



C. Onset of action i.l i.l



D. Therapeutic range i.l




ANS: i . l C PTS: i . l 1

8. Phenytoin requires that a trough level be drawn. Peak and trough levels are done:
i.l i.l i.l i.l i.l i.l i.l i.l i.l i.l i.l i.l i.l



A. When the drug has a wide therapeutic range i.l i.l i.l i.l i.l i.l i.l



B. When the drug will be administered for a short time only i.l i.l i.l i.l i.l i.l i.l i.l i.l i.l



C. When there is a high correlation between the dose and saturation of receptor sites
i.l i.l i.l i.l i.l i.l i.l i.l i.l i.l i.l i.l i.l



D. To determine if a drug is in the therapeutic range
i.l i.l i.l i.l i.l i.l i.l i.l i.l




ANS: i . l D PTS: i . l 1

9. A laboratory result indicates that the peak level for a drug is above the minimum
i.l i.l i.l i.l i.l i.l i.l i.l i.l i.l i.l i.l i.l i.l



toxicconcentration. This means that the:
i.l i.l i.l i.l i.l i.l



A. Concentration will produce therapeutic effects. i.l i.l i.l i.l



B. Concentration will produce an adverse response. i.l i.l i.l i.l i.l



C. Time between doses must be shortened. i.l i.l i.l i.l i.l



D. Duration of action of the drug is too long. i.l i.l i.l i.l i.l i.l i.l i.l




ANS: i . l B PTS: i . l 1

10. Drugs that are receptor agonists may demonstrate what property?
i.l i.l i.l i.l i.l i.l i.l i.l



A. Irreversible binding to the drug receptor site i.l i.l i.l i.l i.l i.l



B. Up-regulation with chronic use i.l i.l i.l



C. Desensitization or down-regulation with continuous use i.l i.l i.l i.l i.l



D. Inverse relationship between drug concentration and drug action i.l i.l i.l i.l i.l i.l i.l




ANS: i . l C PTS: i . l 1

11. Drugs that are receptor antagonists, such as beta blockers, may cause:
i.l i.l i.l i.l i.l i.l i.l i.l i.l i.l



A. Down-regulation of the drug receptor i.l i.l i.l i.l



B. An exaggerated response if abruptly discontinued
i.l i.l i.l i.l i.l



C. Partial blockade of the effects of agonist drugs i.l i.l i.l i.l i.l i.l i.l



D. An exaggerated response to competitive drug agonists
i.l i.l i.l i.l i.l i.l




ANS: i . l B PTS: i . l 1